NCT06080776 2023-10-12
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3 Recruiting
Clinical Trials
4 trialsNCT03823807 2019-02-01
A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2 Unknown
NCT03618043 2019-01-29
Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1 Unknown
NCT03603262 2019-01-28
Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1 Unknown